Mabwell (SSE: 688062) is an innovation-driven biopharmaceutical company, has the whole industrial chain of R&D, manufacturing, and commercialization. We committed to provide more effective and accessible therapy and innovative medicines to fulfill global medical needs.
Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established.
Mabwell has 17 pipeline products in different R&D stages based on a world-class and state-of-the-art R&D engine, including 13 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of auto-immune diseases, oncology, metabolic disorders, ophthalmologic diseases and infectious diseases, etc. Of these, 1 product has been approved and commercialized, 2 products have been filed for MA approval, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and several provincial and municipal science and technological innovation projects.
Mabwell's Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base located in Shanghai is under construction.
First in class product
9MW3011 FDA/NMPA approval for IND; agreement with DISC MEDICINE. Inc with total milestone up to $412.5 million.
Listing on the STAR Market
First Drug Adalimumab Approved for Marketing
Series A Financing
Industrial Capability Established
Taizhou site in place
Initiate Shanghai site construction
Acquisition of PEG platform
Establish US innovation R&D site
Establish ADC platform
Integration of R&D resources
Establish high-throughput drug discovery platform
Initiate Taizhou plant construction
LongRun Investment increased capital into Destiny Bio (Now is New Drug Development Dept.), improve the layout of antibody drug development.
Acquisition of T-mab;
Integration of Kohnoor
Foundation of T-mab
Foundation of Kohnoor
National key research & development project, 2020 & 2021
Biomedical Science and Technology Support Special Project of Shanghai "Science & Technology Innovation Action Plan" in 2020 & 2021
Included in the "List of New and Innovative Chinese Pharmaceutical Forces"
Zhangjiang Life Science Industry New Prominent · 2022
“Sci-Tech Innovation Board Leaders，2022
Biomedical innovation Golden Bud Award
Ranked the List of Top 20 Most Influential Antibody Pharmaceutical Companies in China 2022
TOP100 China Pharmaceutical Innovation Enterprise
TOP100 Companies in STAR Market
TOP100 Awards of Shanghai 1st High Value IP Operation Competition
Included in the “BIGStar 2021 Chinese Most Promising Innovative Biopharmaceutical Enterprises”
TOP30 China Antibody Drug Enterprises of Innovation , 2021 & 2020
Rank 10, China Life Sciences Institutions tables TOP50 (corporate)
Rank 28, Asia Pacific Life Sciences Institutions tables TOP50 (corporate)
BLDG 3, No 576, Libing Rd, Pudong New District, Shanghai, PRC
Ph.D. of Pharmaceutical Chemistry from Shenyang Pharmaceutical University, Post doctor of Tumor Pharmacology from Institute of Materia Medica, Chinese academy of sciences, under two Academicians of Xinsheng Yao and Jian Ding. Dr.Liu has various academic positions including Evaluation Expert of National Technology Award, National Major Science and Technology Funding Projects, as well as Shanghai Investment Consulting Company. Dr. Liu was the Vice President of the Central Research Institute of Shanghai Pharma and General Manager of Shanghai Jiaolian Pharma. Dr.Liu was responsible for around 10 major science projects including the 863 Program (National High-tech R&D Program), National Major Science and Technology Funding Projects, etc. Dr.Liu published over 20 academic papers with 5 patents granted.
Dr. Guo, tutored by Prof. Lianhui Xie, Academician of Chinese Academy of Sciences, obtained her Ph.D. in Pathology. Prior to joining Mabwell, She has held various positions in Biotech, CRO and Biopharm companies, as R&D Director of Tonghua Dongbao Pharmaceutical Co., Ltd, VP of Beijing CLKC Medicine Development Co., Ltd, and CEO of Beijing Oriental TenGen Biomedical Co., Ltd. Dr. Guo was mainly responsible for about 20 IND and NDA applications, approved by CFDA. She took part in National New Drug Innovation Program and others national research projects as PI and Co-PI. She has published more than 20 papers and 16 granted patents for inventions as inventor. She won the honor “High-Level Innovation Talent in Jilin Province” and was the expert for Beijing Science and Technology Progress Award. Dr. Guo is well-experienced in Business Administration, Project Management, HR and Legal Affairs management. As a certified patent agent, she is good at patent strategies.
Dr. Du earned her Ph.D. in Biochemistry from Peking University and received postdoctoral training under Nobel Laureate Dr. Bruce Beutler in UT Southwestern Medical Center. She is a member of the International BioIron Society and American Society of Hematology. Dr. Du has held various positions in Biotech industry and academic institutions, including principal scientist, COI Pharmaceutics; assistant professor, University of California, San Diego; and assistant professor, The Scripps Research Institute. She has more than 20 years’ experience in biomedical research and pharmaceutical R&D, covering a wide range of areas including hematology, iron metabolism, immunology and cancer biology. Dr. Du has authored more than 50 publications.
Dr. Zhang, Antibody drug discovery expert, Ph.D. from Academy of Institute of biotechnology and received postdoctoral training in University of Western Ontario. He is the founder of Beijing Kohnoor Science & Technology Co., Ltd. and has held various positions including researcher in the Institute of biotechnology and Novo Nordisk. He has rich experience in the R&D and application of recombinant protein drugs and has been quite successful in the generation of antibody drug engineering cell line and large scale transient production, construction of large human antibody library, humanization of antibody and affinity maturation. He was involved in the first successful biosimilar FDA IND application from China, received over 10 clinical trial approvals, authored 20 publications and submitted over 15 patent application.
Dr.Wang earned his Ph.D. in Clinical Medicine at Fudan University and is a professor of engineering. He has held various positions in medical industry and academic institutions, including assistant to the president of Fosun Pharma Research Institute, director of Clinical Research Center of the Institute as well as medical director, head of medical registration department and project management department of Sine Pharma of Shanghai Pharma. He has over 15 years’ experience in clinical research, scientific research management and team management. He is quite the expert on GCP and drug registration regulations and is very good at designing clinical research strategies and plans and managing the experiments. He has headed and participated in nearly a dozen of clinical research projects related with major new drug discovery and Shanghai Science and Technology Commission.
Mr.Hu, master of Pharmaceutical Preparations from Shenyang Pharmaceutical University, Mr.Hu was the GM of international business of 3S Pharmaceutical Group, GM of CN-GEN Mab, BD director & International Business GM of CP GUOJIAN, deputy director of Shanghai pharmaceutical Group SINE R&D institute, director of SINE international business, etc., with rich experience in the fields of quality, drug development & industrialization, BD, international RA and sales. Mr. Hu was responsible for the projects of ANDAs, INDs, CTAs, as well as two National Major Science and Technology Funding Projects.
Mr. Li has nearly 30 years of industry experience and 5 years of clinician in Tianjin Second Hospital. He serviced for GSK, Sanofi, Tide and Kelun. In Sanofi, he was the national sales director to manage a thrombosis team of over 1,000 people, with a business scale of more than 3.5 billion，VP and GM of two business divisions in Tide, managed a team of nearly 2,000 people and a business scale of more than 5 billion and as the VP in Kelun, not only in charge of the marketing and medical dept., but also responsible for the establishment of the training and the SFE dept.
Mr. Dong graduated from ECUST, major in chemical pharmacy. He was project Head of CPIDI, vice minister of investment planning for New Asiatic Pharmaceutical, the strategy and investment committee of the board office director, deputy general manager of investment plan, investment result in development for Shanghai Pharmaceuticals Holding Co., Ltd., deputy general manager, deputy general manager of asset management investment development for Shanghai pharmaceutical group Co., Ltd. He has over 30 years of rich experience in biomedical industry construction and fixed assets management.
Mr. Ni served as the director of the production dept. of Hefei Zhaofeng Pharmacy, assistant to chief engineer of Shanghai Wanxing Pharmacy, project manager, GM, chief engineer of 3S GUOJIAN and GM of engineering management dept., GM of CMAB. He has long been engaged in the research and management of biopharmaceutical industrialization technology, with rich experiences in biopharmaceutical technology and equipment, system integration, large-scale biopharmaceutical process development and industrialization.
Ms. Chen, master in Biochemistry and Molecular biology, MBA. Prior to joining Mabwell, Ms. Chen worked for many worldwide famous MNC, GE Healthcare, Roche Diagnostics, Illumina and Thermo Fisher, etc. She was Great China commercial head of Illumina and National sales leader of GE Life Sciences. She has solid management experience in marketing, business development, and sales management in life science and biopharma industry.